Literature DB >> 3886654

Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor).

B A McMullen, K Fujikawa.   

Abstract

The amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor) was determined by automated Edman degradation using the peptides produced by chemical and enzymatic cleavages of intact factor XII and alpha-factor XIIa. Combining this sequence with the previously determined sequence of beta-factor XIIa (Fujikawa, K., and McMullen, B. A. (1983) J. Biol. Chem. 258, 10924-10933), the complete amino acid sequence of human factor XII has been established. The heavy chain of alpha-factor XIIa is composed of 353 amino acid residues containing one Asn-linked and six probable O-linked carbohydrate chains. The heavy chain of alpha-factor XIIa appears to contain four different domains including a "kringle," a "growth factor" domain, and the "type I" and "type II" domains of fibronectin. The domain organization of factor XII is analogous to those of several fibrinolytic proteins, including tissue plasminogen activator and urokinase, suggesting that factor XII belongs to the same protease subfamily as these two proteins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886654

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Origin of fibronectin type II (FN2) modules: structural analyses of distantly-related members of the kringle family idey the kringle domain of neurotrypsin as a potential link between FN2 domains and kringles.

Authors:  O A Ozhogina; M Trexler; L Bányai; M Llinás; L Patthy
Journal:  Protein Sci       Date:  2001-10       Impact factor: 6.725

2.  The search for a new model structure of beta-factor XIIa.

Authors:  E S Henriques; W B Floriano; N Reuter; A Melo; D Brown; J A Gomes; B Maigret; M A Nascimento; M J Ramos
Journal:  J Comput Aided Mol Des       Date:  2001-04       Impact factor: 3.686

3.  Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase.

Authors:  Volker Pönitz; David Pritchard; Heidi Grundt; Dennis Winston T Nilsen
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

4.  Sequence of the notch locus of Drosophila melanogaster: relationship of the encoded protein to mammalian clotting and growth factors.

Authors:  S Kidd; M R Kelley; M W Young
Journal:  Mol Cell Biol       Date:  1986-09       Impact factor: 4.272

Review 5.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

6.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

7.  Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin.

Authors:  W H Kane; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor.

Authors:  P Chien; R A Pixley; L G Stumpo; R W Colman; A D Schreiber
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

9.  Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution.

Authors:  T Miyata; S Kawabata; S Iwanaga; I Takahashi; B Alving; H Saito
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.